← All trials
NCT06745908
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2025
- Primary completion
- Sep 30, 2028
- Completion date
- Jan 31, 2029
- First posted
- Dec 20, 2024
- Last posted
- Feb 17, 2025
- Enrollment
- 460
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ImmunityBio, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.